Repligen (NASDAQ:RGEN) Announces Earnings Results

Repligen (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05, FiscalAI reports. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the business earned $0.44 EPS. Repligen’s revenue for the quarter was up 18.1% on a year-over-year basis. Repligen updated its FY 2026 guidance to 1.930-2.010 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen finished 2025 strongly with $198M in Q4 and $738M for the year, delivering 16% reported and organic non-COVID growth and beating the high end of prior guidance.
• Franchise momentum was broad-based: proteins and analytics grew >30% in Q4, chromatography >25%, and management highlighted a multi-year upgrade cycle for the SoloVPE PLUS and benefits from the 908 Devices acquisition.
• 2026 guidance expects $810M–$840M revenue (9%–13% organic), ~150 bps operating margin expansion at the midpoint, and adjusted EPS of $1.93–$2.01, signaling continued top-line and margin improvement.
• Key near-term risks include a ~2–3 point headwind from a gene therapy platform, expected tariff surcharges (~50 bps margin impact), and uncertainty from MFN/FDA-related customer capex timing that could damp growth.
• Balance sheet and capital strategy: $768M in cash/marketable securities, an active M&A pipeline (priority for 2026), and continued investments in IT, AI, services and commercial expansion to support future growth.

Repligen Stock Performance

NASDAQ RGEN opened at $132.14 on Thursday. The company has a quick ratio of 7.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $102.96 and a 52-week high of $175.77. The business’s 50-day moving average price is $155.34 and its 200 day moving average price is $146.77. The firm has a market cap of $7.44 billion, a P/E ratio of 155.46, a P/E/G ratio of 2.54 and a beta of 1.13.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGEN. Canaccord Genuity Group upped their price target on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday. UBS Group lowered their target price on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Finally, Barclays reduced their price target on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Key Headlines Impacting Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q4 beat and healthy revenue growth — Repligen reported $0.49 EPS vs. $0.44 expected and revenue of $197.9M (up ~18% y/y), with improving margins and organic growth that supports the company’s execution thesis. Read More.
• Positive Sentiment: Analysts largely still constructive — several firms kept buy/overweight ratings and multi‑dozen percent upside from current levels (TD Cowen maintained a Buy / $200 PT; UBS retained a Buy though trimmed its PT). This suggests many investors and analysts still view longer‑term growth as intact. Read More.
• Neutral Sentiment: Narrative shift — coverage highlights new M&A targets and product opportunities that management discussed as part of a shifting strategic narrative; such optionality could be positive but is uncertain and longer‑dated. Read More.
• Neutral Sentiment: Earnings call/transcripts available — full call transcripts and summaries show management’s tone of confidence on execution but emphasize prudent guidance; useful for parsing management conviction and cadence. Read More.
• Neutral Sentiment: Price-target trims but ratings largely intact — UBS cut its target to $195, Barclays to $175 and Wells Fargo to $180, yet most kept buy/overweight stances, leaving sizeable upside scenarios intact if growth accelerates. Read More. • Read More.
• Negative Sentiment: Cautious FY2026 guidance — Repligen set FY26 EPS at $1.93–2.01 and revenue $810–840M, both slightly below consensus (consensus EPS ≈ $2.06; revenue ~ $822.8M). The softer guidance is the primary reason for near‑term selling pressure. Read More.
• Negative Sentiment: Valuation concerns and limited near‑term upside — some analysts (Canaccord) flag a premium valuation and say upside is constrained at current prices, which may cap multiple expansion absent stronger guidance or visible M&A. Read More.
• Negative Sentiment: Short‑term sell‑off reaction — multiple news pieces note an immediate post‑earnings pullback (coverage explains a sharp intraday drop as investors reprice the stock to the new guidance). Read More.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently modified their holdings of RGEN. Pacer Advisors Inc. increased its stake in Repligen by 2.5% in the 4th quarter. Pacer Advisors Inc. now owns 10,469 shares of the biotechnology company’s stock valued at $1,715,000 after buying an additional 256 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Repligen by 12.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock valued at $105,874,000 after acquiring an additional 74,044 shares in the last quarter. Compound Planning Inc. acquired a new position in shares of Repligen during the fourth quarter worth about $204,000. Invesco Ltd. increased its stake in shares of Repligen by 43.9% during the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after acquiring an additional 383,399 shares during the period. Finally, Alpine Woods Capital Investors LLC purchased a new position in Repligen during the fourth quarter worth about $1,005,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.